CoChat
Sign Up
Cited by 70

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Oral lipid nanomedicines: Current status and future perspectives in cancer treatment

El Moukhtari, Souhaila H., Rodríguez-Nogales, Carlos, Blanco-Prieto, María J.·2021·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2021.03.004
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2021.03.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Fig. 1 Schematic illustrations of the most frequently described types of lipid nanoparticles (LNPs). From left to right: solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid drug conjugate lipid nanoparticles (LDCs) and polymer-lipid hybrid nanoparticles.
Fig. 1 Schematic illustrations of the most frequently described types of lipid nanoparticles (LNPs). From left to right: solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid drug conjugate lipid nanoparticles (LDCs) and polymer-lipid hybrid nanoparticles.CC-BY-NC-ND · From the PDF
Fig 2 Oral absorption of nanomedicines. The illustration shows polyethylen glycol (PEG)ylated SLNs loaded with a chemotherapeutic drug reaching and penetrating the gastrointestinal mucus barrier.
Fig 2 Oral absorption of nanomedicines. The illustration shows polyethylen glycol (PEG)ylated SLNs loaded with a chemotherapeutic drug reaching and penetrating the gastrointestinal mucus barrier.CC-BY-NC-ND · From the PDF
Fig 3 Comparison between intravenous administration of conventional chemotherapy, chemotherapeutic loaded nanoparticles administered intravenously, oral conventional chemotherapy and chemotherapeutic loaded nanoparticles administered orally.
Fig 3 Comparison between intravenous administration of conventional chemotherapy, chemotherapeutic loaded nanoparticles administered intravenously, oral conventional chemotherapy and chemotherapeutic loaded nanoparticles administered orally.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 158

  1. Burdett, 2008, Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials, J. Clin. Oncol., 26, 4617, 10.1200/JCO.2008.17.7162 · DOI · Paper page
  2. Hassett, 2011, Chemotherapy-related hospitalization among community cancer center patients, Oncologist, 16, 378, 10.1634/theoncologist.2010-0354 · DOI
  3. Banna, 2010, Anticancer oral therapy: Emerging related issues, Cancer Treat. Rev., 36, 595, 10.1016/j.ctrv.2010.04.005 · DOI
  4. V. Gebbia, V. Gebbia, Borsellino, Ferrau’, Verderame, Butera, Giuffrida, P. Tralongo, Cancer patient-centered home care: a new model for health care in oncology, Ther. Clin. Risk Manag. (2011) 387–392. 10.2147/TCRM.S22119. · DOI
  5. Bergeson, 2006, A systems approach to patient-centered care, J. Am. Med. Assoc., 296, 2848, 10.1001/jama.296.23.2848 · DOI
  6. Liu, 1997, Patient preferences for oral versus intravenous palliative chemotherapy, J. Clin. Oncol., 15, 110, 10.1200/JCO.1997.15.1.110 · DOI
  7. Kaur, 2019, Oral drug delivery technologies—A decade of developments, J. Pharmacol. Exp. Ther., 370, 529, 10.1124/jpet.118.255828 · DOI
  8. Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 · DOI · Paper page
  9. Kim, 2017, Overcoming key biological barriers to cancer drug delivery and efficacy, J. Control. Release, 267, 15, 10.1016/j.jconrel.2017.09.016 · DOI
  10. Thanki, 2013, Oral delivery of anticancer drugs: Challenges and opportunities, J. Control. Release, 170, 15, 10.1016/j.jconrel.2013.04.020 · DOI
  11. Shi, 2017, Cancer nanomedicine: Progress, challenges and opportunities, Nat. Rev. Cancer, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  12. Das, 2011, Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery, AAPS PharmSciTech, 12, 62, 10.1208/s12249-010-9563-0 · DOI
  13. Dawidczyk, 2014, Nanomedicines for cancer therapy: State-of-the-art and limitations to pre-clinical studies that hinder future developments, Front. Chem., 2, 69, 10.3389/fchem.2014.00069 · DOI
  14. Xu, 2015, Cancer nanomedicine: From targeted delivery to combination therapy, Trends Mol. Med., 21, 223, 10.1016/j.molmed.2015.01.001 · DOI · Paper page
  15. Müller, 2000, Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art, Eur. J. Pharm. Biopharm., 50, 161, 10.1016/S0939-6411(00)00087-4 · DOI
  16. Wissing, 2004, Solid lipid nanoparticles for parenteral drug delivery, Adv. Drug Deliv. Rev., 56, 1257, 10.1016/j.addr.2003.12.002 · DOI
  17. Salah, 2020, Solid lipid nanoparticles for enhanced oral absorption: A review, Colloids Surfaces B Biointerfaces., 196, 111305, 10.1016/j.colsurfb.2020.111305 · DOI
  18. Nasirizadeh, 2020, Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery, J. Drug Deliv. Sci. Technol., 55, 101458, 10.1016/j.jddst.2019.101458 · DOI
  19. Ganesan, 2017, Lipid nanoparticles: Different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery, Sustain. Chem. Pharm., 6, 37, 10.1016/j.scp.2017.07.002 · DOI
  20. Harde, 2011, Solid lipid nanoparticles: an oral bioavailability enhancer vehicle, Expert Opin. Drug Deliv., 8, 1407, 10.1517/17425247.2011.604311 · DOI
  21. Lasa-Saracibar, 2012, Lipid nanoparticles for cancer therapy: State of the art and future prospects, Expert Opin. Drug Deliv., 9, 1245, 10.1517/17425247.2012.717928 · DOI
  22. Lin, 2017, Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers, J. Food Drug Anal., 25, 219, 10.1016/j.jfda.2017.02.001 · DOI
  23. N. Poonia, R. Kharb, V. Lather, D. Pandita, Nanostructured lipid carriers: versatile oral delivery vehicle, Futur. Sci. OA. 2 (2016) FSO135. Doi: 10.4155/fsoa-2016-0030. · DOI
  24. Irby, 2017, Lipid-drug conjugate for enhancing drug delivery, Mol. Pharm., 14, 1325, 10.1021/acs.molpharmaceut.6b01027 · DOI
  25. Dave, 2019, Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications, J. Microbiol. Methods, 160, 130, 10.1016/j.mimet.2019.03.017 · DOI
  26. Scioli Montoto, 2020, Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects, Front. Mol. Biosci., 7, 1, 10.3389/fmolb.2020.587997 · DOI
  27. Lu, 2012, Absorption, Disposition and Pharmacokinetics of Nanoemulsions, Curr. Drug Metab., 13, 396, 10.2174/138920012800166544 · DOI
  28. Vertzoni, 2019, Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review, Eur. J. Pharm. Sci., 134, 153, 10.1016/j.ejps.2019.04.013 · DOI
  29. Johansson, 2013, The gastrointestinal mucus system in health and disease, Nat. Rev. Gastroenterol. Hepatol., 10, 352, 10.1038/nrgastro.2013.35 · DOI · Paper page
  30. Pearson, 2016, The properties of the mucus barrier, a unique gel - how can nanoparticles cross it?, Ther. Deliv., 7, 229, 10.4155/tde-2015-0002 · DOI
  31. Bansil, 2018, The biology of mucus: Composition, synthesis and organization, Adv. Drug Deliv. Rev., 124, 3, 10.1016/j.addr.2017.09.023 · DOI
  32. Atuma, 2001, The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo, Am. J. Physiol. – Gastrointest. Liver Physiol., 280, G922, 10.1152/ajpgi.2001.280.5.G922 · DOI
  33. Boegh, 2015, Mucus as a barrier to drug delivery - Understanding and mimicking the barrier properties, Basic Clin. Pharmacol. Toxicol., 116, 179, 10.1111/bcpt.12342 · DOI
  34. Wagner, 2018, Mucins and Their Role in Shaping the Functions of Mucus Barriers, Annu. Rev. Cell Dev. Biol., 34, 189, 10.1146/annurev-cellbio-100617-062818 · DOI
  35. Boegh, 2015, Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation, Eur. J. Pharm. Biopharm., 95, 136, 10.1016/j.ejpb.2015.01.014 · DOI
  36. Li, 2013, Spatial configuration and composition of charge modulates transport into a mucin hydrogel barrier, Biophys. J., 105, 1357, 10.1016/j.bpj.2013.07.050 · DOI
  37. Hens, 2017, Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities, Int. J. Pharm., 519, 79, 10.1016/j.ijpharm.2016.11.063 · DOI
  38. D’Souza, 2014, A Review of In Vitro Drug Release Test Methods for Nano-Sized Dosage Forms, Adv. Pharm., 2014, 1
  39. Dumont, 2019, In-vitro evaluation of solid lipid nanoparticles: Ability to encapsulate, release and ensure effective protection of peptides in the gastrointestinal tract, Int. J. Pharm., 565, 409, 10.1016/j.ijpharm.2019.05.037 · DOI
  40. Shen, 2016, Decorating nanoparticle surface for targeted drug delivery: Opportunities and challenges, Polymers (Basel), 8, 1, 10.3390/polym8030083 · DOI
  41. Luo, 2015, Solid lipid nanoparticles for oral drug delivery: Chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake, Carbohydr. Polym., 122, 221, 10.1016/j.carbpol.2014.12.084 · DOI
  42. Ramalingam, 2015, Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: Pharmacokinetic and brain distribution evaluations, Pharm. Res., 32, 389, 10.1007/s11095-014-1469-1 · DOI
  43. Senthil Kumar, 2020, Targeted delivery and apoptosis induction of trans-resveratrol-ferulic acid loaded chitosan coated folic acid conjugate solid lipid nanoparticles in colon cancer cells, Carbohydr. Polym., 231, 115682, 10.1016/j.carbpol.2019.115682 · DOI · Paper page
  44. Baek, 2017, Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake, Eur. J. Pharm. Biopharm., 117, 132, 10.1016/j.ejpb.2017.04.013 · DOI
  45. Moss, 2018, The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery, Expert Rev. Gastroenterol. Hepatol., 12, 223, 10.1080/17474124.2018.1399794 · DOI
  46. A.A. D’souza, R. Shegokar, Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications, Expert Opin. Drug Deliv. 13 (2016) 1257–1275. Doi: 10.1080/17425247.2016.1182485. · DOI · Paper page
  47. Huckaby, 2018, PEGylation for enhancing nanoparticle diffusion in mucus, Adv. Drug Deliv. Rev., 124, 125, 10.1016/j.addr.2017.08.010 · DOI
  48. Khutoryanskiy, 2018, Beyond PEGylation: Alternative surface-modification of nanoparticles with mucus-inert biomaterials, Adv. Drug Deliv. Rev., 124, 140, 10.1016/j.addr.2017.07.015 · DOI
  49. Yu, 2019, Effect of Surface Charges on Oral Absorption of Intact Solid Lipid Nanoparticles, Mol. Pharm., 16, 5013, 10.1021/acs.molpharmaceut.9b00861 · DOI
  50. Zhang, 2019, Modulating intestinal mucus barrier for nanoparticles penetration by surfactants, Asian J. Pharm. Sci., 14, 543
  51. Estella-Hermoso de Mendoza, 2011, In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma, J. Control. Release, 156, 421, 10.1016/j.jconrel.2011.07.030 · DOI
  52. González-Fernández, 2018, Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma, Cancer Lett., 430, 193, 10.1016/j.canlet.2018.05.030 · DOI
  53. Menzel, 2018, Enzyme decorated drug carriers: Targeted swords to cleave and overcome the mucus barrier, Adv. Drug Deliv. Rev., 124, 164, 10.1016/j.addr.2017.10.004 · DOI
  54. Pereira De Sousa, 2015, Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier, Eur. J. Pharm. Biopharm., 97, 257, 10.1016/j.ejpb.2015.01.008 · DOI
  55. Patel, 2018, Lipid-Based Oral Formulation Strategies for Lipophilic Drugs, AAPS PharmSciTech, 19, 3609, 10.1208/s12249-018-1188-8 · DOI
  56. Karamanidou, 2016, Lipid-based nanocarriers for the oral administration of biopharmaceutics, Nanomedicine, 11, 3009, 10.2217/nnm-2016-0265 · DOI
  57. Vishwakarma, 2019, Lipid-Based Nanocarriers for Lymphatic Transportation, AAPS PharmSciTech, 20, 83, 10.1208/s12249-019-1293-3 · DOI
  58. Kim, 2018, Oral Nanoparticles Exhibit Specific High-Efficiency Intestinal Uptake and Lymphatic Transport, ACS Nano, 12, 8893, 10.1021/acsnano.8b04315 · DOI
  59. Carlson, 1983, Continuous Infusion or Bolus Injection in Cancer Chemotherapy, Ann. Intern. Med., 99, 823, 10.7326/0003-4819-99-6-823 · DOI
  60. Huitema, 2002, Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin, Ann. Oncol., 13, 374, 10.1093/annonc/mdf052 · DOI
  61. Lee, 2020, Is There a Role for Chemotherapy in the Era of Targeted Therapies?, Curr. Hematol. Malig. Rep., 15, 72, 10.1007/s11899-020-00563-8 · DOI
  62. Van Tellingen, 1999, Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients, Br. J. Cancer, 81, 330, 10.1038/sj.bjc.6690696 · DOI
  63. Picard, 2015, Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review, Clin. Rev. Allergy Immunol., 49, 177, 10.1007/s12016-014-8416-0 · DOI
  64. von Pawel, 2001, Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer, J. Clin. Oncol., 19, 1743, 10.1200/JCO.2001.19.6.1743 · DOI
  65. Gackowski, 2021, Pharmacological classification of anticancer drugs applying chromatographic retention data and chemometric analysis, Chem. Pap., 75, 265, 10.1007/s11696-020-01301-3 · DOI
  66. Surapaneni, 2012, Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges, ISRN Pharmacol., 2012, 1, 10.5402/2012/623139 · DOI
  67. Feng, 2013, A critical review of lipid-based nanoparticles for taxane delivery, Cancer Lett., 334, 157, 10.1016/j.canlet.2012.07.006 · DOI
  68. Anselmo, 2019, Nanoparticles in the clinic: An update, Bioeng. Transl. Med., 4, 1, 10.1002/btm2.10143 · DOI · Paper page
  69. ten Tije, 2003, Pharmacological Effects of Formulation Vehicles, Clin. Pharmacokinet., 42, 665, 10.2165/00003088-200342070-00005 · DOI
  70. Kuppens, 2005, Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093), Cancer Chemother. Pharmacol., 55, 72, 10.1007/s00280-004-0864-4 · DOI
  71. Cho, 2014, Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: Enhanced intestinal absorption and lymphatic uptake, Int. J. Nanomed., 9, 495
  72. Shi, 2017, Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel, Drug Dev. Ind. Pharm., 43, 839, 10.1080/03639045.2016.1220571 · DOI
  73. Keck, 2013, Nanotoxicological classification system (NCS) - A guide for the risk-benefit assessment of nanoparticulate drug delivery systems, Eur. J. Pharm. Biopharm., 84, 445, 10.1016/j.ejpb.2013.01.001 · DOI
  74. Kim, 2019, Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle, J. Control. Release, 10.1016/j.jconrel.2019.08.027 · DOI
  75. Benet, 1999, Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery, J. Control. Release, 62, 25, 10.1016/S0168-3659(99)00034-6 · DOI
  76. Shukla, 2011, Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters, Curr. Drug Targets, 12, 621, 10.2174/138945011795378540 · DOI
  77. Pandita, 2011, Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel, AAPS PharmSciTech, 12, 712, 10.1208/s12249-011-9636-8 · DOI
  78. Pooja, 2016, Improving efficacy, oral bioavailability, and delivery of paclitaxel using protein-grafted solid lipid nanoparticles, Mol. Pharm., 13, 3903, 10.1021/acs.molpharmaceut.6b00691 · DOI
  79. Brück, 2001, Lectin-Functionalized Liposomes for Pulmonary Drug Delivery: Interaction with Human Alveolar Epithelial Cells, J. Drug Target, 9, 241, 10.3109/10611860108997933 · DOI
  80. Liu, 2011, Bioadhesion and enhanced bioavailability by wheat germ agglutinin-grafted lipid nanoparticles for oral delivery of poorly water-soluble drug bufalin, Int. J. Pharm., 419, 260, 10.1016/j.ijpharm.2011.07.019 · DOI
  81. Dastidar, 2019, Paclitaxel-encapsulated core-shell nanoparticle of cetyl alcohol for active targeted delivery through oral route, Nanomedicine, 14, 2121, 10.2217/nnm-2018-0419 · DOI
  82. Sun, 2016, Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel, Colloids Surf. B Biointerfaces, 143, 47, 10.1016/j.colsurfb.2016.02.065 · DOI
  83. J. Gou, S. Feng, Y. Liang, G. Fang, H. Zhang, T. Yin, Y. Zhang, H. He, Y. Wang, X. Tang, Polyester – Solid Lipid Mixed Nanoparticles with Improved Stability in Gastro-Intestinal Tract Facilitated Oral Delivery of Larotaxel, (2017) 3750–3761. Doi: 10.1021/acs.molpharmaceut.7b00503. · DOI
  84. Baek, 2012, Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system, Int. J. Mol. Med., 30, 953, 10.3892/ijmm.2012.1086 · DOI
  85. Schirrmacher, 2019, From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review), Int. J. Oncol., 54, 407, 10.3892/ijo.2018.4661 · DOI
  86. V.J. O’neill, C.J. Twelves, Oral cancer treatment: Developments in chemotherapy and beyond, Br. J. Cancer. 87 (2002) 933–937. Doi: 10.1038/sj.bjc.6600591. · DOI
  87. Gabizon, 2012, Pharmacological basis of pegylated liposomal doxorubicin: Impact on cancer therapy, Eur. J. Pharm. Sci., 45, 388, 10.1016/j.ejps.2011.09.006 · DOI
  88. Zhang, 2017, Development, characterization and evaluation of doxorubicin nanostructured lipid carriers for prostate cancer, Jbuon, 22, 102
  89. Toffoli, 2004, Pharmacokinetic optimisation of treatment with oral etoposide, Clin. Pharmacokinet., 43, 441, 10.2165/00003088-200443070-00002 · DOI
  90. Harvey, 1986, The effect of dose on the bioavailability of oral etoposide, Cancer Chemother. Pharmacol., 16, 178, 10.1007/BF00256172 · DOI
  91. Hande, 1993, Bioavailability of low-dose oral etoposide, J. Clin. Oncol., 11, 374, 10.1200/JCO.1993.11.2.374 · DOI
  92. Joel, 1994, Etoposide dosage and pharmacodynamics, Cancer Chemother. Pharmacol., 34, 27, 10.1007/BF00684867 · DOI
  93. Zhang, 2011, Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide, Eur. J. Pharm. Sci., 43, 174, 10.1016/j.ejps.2011.04.005 · DOI
  94. Prendiville, 1997, Gemcitabine, Br. J. Hosp. Med., 57, 405
  95. Veltkamp, 2008, Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice, Drug Metab. Dispos., 36, 1606, 10.1124/dmd.108.021048 · DOI
  96. Wang, 2017, Oral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models, Oncotarget, 8, 89876, 10.18632/oncotarget.21264 · DOI
  97. Rajpoot, 2020, Oral delivery of pH-responsive alginate microbeads incorporating folic acid-grafted solid lipid nanoparticles exhibits enhanced targeting effect against colorectal cancer: A dual-targeted approach, Int. J. Biol. Macromol., 151, 830, 10.1016/j.ijbiomac.2020.02.132 · DOI
  98. Yuan, 2013, Improved transport and absorption through gastrointestinal tract by pegylated solid lipid nanoparticles, Mol. Pharm., 10, 1865, 10.1021/mp300649z · DOI
  99. Gidwani, 2020, Cytotoxicity and pharmacokinetics study of nanostructured lipid carriers of mechlorethamine: Preparation, optimization and characterization, Part. Sci. Technol., 38, 23, 10.1080/02726351.2018.1536685 · DOI
  100. Soni, 2017, Lipid drug conjugate nanoparticle as a potential nanocarrier for the oral delivery of pemetrexed diacid: Formulation design, characterization, ex vivo, and in vivo assessment, Int. J. Biol. Macromol., 103, 139, 10.1016/j.ijbiomac.2017.05.015 · DOI
  101. Bedard, 2020, Small molecules, big impact: 20 years of targeted therapy in oncology, Lancet, 395, 1078, 10.1016/S0140-6736(20)30164-1 · DOI
  102. Grant, 2007, Vorinostat, Nat. Rev. Drug Discov., 6, 21, 10.1038/nrd2227 · DOI
  103. Tran, 2014, Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant, Cancer Cells, 1978
  104. Keating, 2009, Sorafenib: A review of its use in advanced hepatocellular carcinoma, Drugs, 69, 223, 10.2165/00003495-200969020-00006 · DOI
  105. Tunki, 2019, Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment, Eur. J. Pharm. Sci., 137, 104978, 10.1016/j.ejps.2019.104978 · DOI
  106. D’Souza, 2015, Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications, J. Control. Release, 203, 126, 10.1016/j.jconrel.2015.02.022 · DOI
  107. Garbayo, 2020, Nanomedicine and drug delivery systems in cancer and regenerative medicine, Wiley Interdiscip. Rev. Nanomedicine, Nanobiotechnology, 1
  108. Lasa-Saracíbar, 2014, Lipid nanoparticles protect from edelfosine toxicity in vivo, Int. J. Pharm., 474, 1, 10.1016/j.ijpharm.2014.07.053 · DOI
  109. Rodríguez-Nogales, 2018, Nanomedicines for Pediatric Cancers, ACS Nano, 12, 7482, 10.1021/acsnano.8b03684 · DOI
  110. Singh, 2019, Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies, J. Pharm. Sci., 108, 3382, 10.1016/j.xphs.2019.06.003 · DOI
  111. B. Gupta, B.K. Poudel, T.H. Tran, R. Pradhan, H. Cho, J. Jeong, B.S. Shin, H. Choi, Modulation of Pharmacokinetic and Cytotoxicity Prof ile of Imatinib Base by Employing Optimized Nanostructured Lipid Carriers (2015) 2912–2927. Doi: 10.1007/s11095-015-1673-7. · DOI
  112. Vivek, 2018, Development, Evaluation and Targeting of Imatinib Mesylate Loaded Solid Lipid Nanoparticles To the Lymphatic System, Int. J. Pharm. Sci. Res., 9, 2359
  113. Azandaryani, 2019, A Comprehensive Physicochemical, In Vitro and Molecular Characterization of Letrozole Incorporated Chitosan-Lipid Nanocomplex, Pharm. Res., 36, 62, 10.1007/s11095-019-2597-4 · DOI
  114. Hashem, 2014, In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate, Pharm. Dev. Technol., 19, 824, 10.3109/10837450.2013.836218 · DOI
  115. Mokhtari, 2017, Combination therapy in combating cancer, Oncotarget, 8, 38022, 10.18632/oncotarget.16723 · DOI · Paper page
  116. Carrick, 2009, Single agent versus combination chemotherapy for metastatic breast cancer, Cochrane Database Syst. Rev.
  117. Hu, 2012, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer, Biochem. Pharmacol., 83, 1104, 10.1016/j.bcp.2012.01.008 · DOI
  118. Naguib, 2016, Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2’, 2’-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity, Neoplasia, 18, 33, 10.1016/j.neo.2015.11.012 · DOI
  119. Newell, 2017, A critical review on the effect of docosahexaenoic acid (Dha) on cancer cell cycle progression, Int. J. Mol. Sci., 18, 1, 10.3390/ijms18081784 · DOI
  120. Valdes, 2019, A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2′, 2′-difluorodeoxycytidine with increased solubility, stability, and antitumor activity, Int. J. Pharm., 570, 118609, 10.1016/j.ijpharm.2019.118609 · DOI
  121. Valdes, 2020, Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine After Oral Administration, AAPS PharmSciTech, 21, 77, 10.1208/s12249-020-1617-3 · DOI
  122. Khatri, 2020, Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy, Int. J. Pharm., 583, 119386, 10.1016/j.ijpharm.2020.119386 · DOI
  123. Farsam, 2011, Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4 + CD25 + FoxP3 + T reg cells in vivo, Int. Immunopharmacol., 11, 1802, 10.1016/j.intimp.2011.07.008 · DOI
  124. Crain, 2018, Daunorubicin & Cytarabine Liposome (VyxeosTM), Oncol. Times., 40, 30, 10.1097/01.COT.0000534146.30839.ec · DOI
  125. Shen, 2019, Hierarchically targetable polysaccharide-coated solid lipid nanoparticles as an oral chemo/thermotherapy delivery system for local treatment of colon cancer, Biomaterials, 197, 86, 10.1016/j.biomaterials.2019.01.019 · DOI
  126. A. Dhaundiyal, S.K. Jena, S.K. Samal, B. Sonvane, M. Chand, Alpha-lipoic acid – stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery : formulation , optimization , in-vivo pharmacokinetic and hepatotoxicity study, 68 (2016) 1535–1550. Doi: 10.1111/jphp.12644. · DOI
  127. Lagoa, 2020, Advances in phytochemical delivery systems for improved anticancer activity, Biotechnol. Adv., 38, 107382, 10.1016/j.biotechadv.2019.04.004 · DOI
  128. Cragg, 1998, Paclitaxel (Taxol®): A success story with valuable lessons for natural product drug discovery and development, Med. Res. Rev., 18, 315, 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO;2-W · DOI
  129. Giordano, Tommonaro, Curcumin and Cancer, Nutrients. 11 (2019) 2376. Doi: 10.3390/nu11102376. · DOI
  130. Ma, 2019, Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application, J. Control. Release, 316, 359, 10.1016/j.jconrel.2019.10.053 · DOI
  131. Kakkar, 2011, Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin, Mol. Nutr. Food Res., 55, 495, 10.1002/mnfr.201000310 · DOI
  132. Ban, 2020, Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles, Food Chem., 302, 125328, 10.1016/j.foodchem.2019.125328 · DOI
  133. Dorai, 2004, Role of chemopreventive agents in cancer therapy, Cancer Lett., 215, 129, 10.1016/j.canlet.2004.07.013 · DOI
  134. Walle, 2011, Bioavailability of resveratrol, Ann. N. Y. Acad. Sci., 1215, 9, 10.1111/j.1749-6632.2010.05842.x · DOI · Paper page
  135. Ko, 2017, The role of resveratrol in cancer therapy, Int. J. Mol. Sci., 18, 1, 10.3390/ijms18122589 · DOI
  136. Srinivasan, 2007, Ferulic acid: Therapeutic potential through its antioxidant property, J. Clin. Biochem. Nutr., 40, 92, 10.3164/jcbn.40.92 · DOI
  137. S.M. Godugu, C. Doddapaneni, R. Safe SH, Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer, Eur. J. Pharm. Biopharm. 108 (2016) 168–179. Doi: 10.1016/j.physbeh.2017.03.040. · DOI
  138. Soni, 2018, Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments, Artif. Cells, Nanomed. Biotechnol., 46, 15, 10.1080/21691401.2017.1408124 · DOI
  139. Jiang, 2019, Anti-cancer effects of 3,3’-diindolylmethane on human hepatocellular carcinoma cells is enhanced by calcium ionophore: The role of cytosolic Ca2+ and P38 mapk, Front. Pharmacol., 10, 1, 10.3389/fphar.2019.01167 · DOI
  140. Thomson, 2016, Chemopreventive properties of 3,30-diindolylmethane in breast cancer: Evidence from experimental and human studies, Nutr. Rev., 74, 432, 10.1093/nutrit/nuw010 · DOI
  141. Khan, 2018, PhytoNanotechnology: Enhancing delivery of plant based anti-cancer drugs, Front. Pharmacol., 8, 1002, 10.3389/fphar.2017.01002 · DOI
  142. Z. Wang, H. Fan, Y. Li, Y. Wang, Anti-hepatocarcinoma effects of chrysin loaded solid lipid nanoparticle against H22 tumor bearing mice, (2015) 1020–1024. Doi: 10.2991/ic3me-15.2015.197. · DOI
  143. Nordin, 2020, Antitumor and Anti-Metastatic Effects of Citral-Loaded Nanostructured Lipid Carrier in 4T1-Induced Breast Cancer Mouse Model, Molecules, 25, 1, 10.3390/molecules25112670 · DOI
  144. Ramesh, 2019, Pharmacokinetic, toxicokinetic, and bioavailability studies of epigallocatechin-3-gallate loaded solid lipid nanoparticle in rat model, Drug Dev. Ind. Pharm., 45, 1506, 10.1080/03639045.2019.1634091 · DOI
  145. Poonia, 2019, Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation, Colloids Surf. B Biointerfaces, 181, 756, 10.1016/j.colsurfb.2019.06.004 · DOI
  146. Weingart, 2008, NCCN, Task Force Report: Oral Chemotherapy, J. Natl. Compr. Cancer Netw., 6
  147. Patel, 2013, Oral cancer chemotherapy adherence and adherence assessment tools: A report from north central cancer group trial n0747 and a systematic review of the literature, J. Cancer Educ., 28, 770, 10.1007/s13187-013-0511-z · DOI
  148. Skrabal Ross, 2020, A review of factors influencing non-adherence to oral antineoplastic drugs, Support. Care Cancer, 28, 4043
  149. Rabbie, 2015, Inter-subject variability in intestinal drug solubility, Int. J. Pharm., 485, 229, 10.1016/j.ijpharm.2015.03.006 · DOI
  150. Homayun, 2019, Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals, Pharmaceutics, 11, 129, 10.3390/pharmaceutics11030129 · DOI · Paper page
  151. Kumar, 2017, Editorial – Metronomic chemotherapy, Cancer Lett., 400, 203, 10.1016/j.canlet.2017.03.003 · DOI
  152. Pasquier, 2010, Metronomic chemotherapy: New rationale for new directions, Nat. Rev. Clin. Oncol., 7, 455, 10.1038/nrclinonc.2010.82 · DOI
  153. Simsek, 2019, Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience, J. Oncol., 2019, 1, 10.1155/2019/5483791 · DOI
  154. Abu Lila, 2017, Metronomic chemotherapy and nanocarrier platforms, Cancer Lett., 400, 232, 10.1016/j.canlet.2016.11.007 · DOI
  155. Ng, 2006, Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel, Clin. Cancer Res., 12, 4331, 10.1158/1078-0432.CCR-05-2762 · DOI
  156. Salvioni, 2019, Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope, Cancers (Basel), 11, 1855, 10.3390/cancers11121855 · DOI
  157. Farjadian, 2019, Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities, Nanomedicine, 14, 93, 10.2217/nnm-2018-0120 · DOI
  158. Kang, 2018, Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy, Ann. Oncol., 29, 1220, 10.1093/annonc/mdy055 · DOI

Cited by

Sorted by citations

Metadata

Authors
El Moukhtari, S. H., Rodríguez-Nogales, C., & Blanco-Prieto, M. J.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2021-06
Volume
173
Pages
238-251
ISSN
0169-409X
DOI
10.1016/j.addr.2021.03.004
Cited by
70
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review